Dare Bioscience, Inc. Common Stock

DARENASDAQUSD
1.34 USD
0.62 (31.60%)AT CLOSE (11:59 AM EDT)
1.37
0.03 (1.94%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
1.37
0.03 (1.94%)
🔴Market: CLOSED

Dare Bioscience, Inc. Common Stock (DARE) is currently trading at $1.34. Technicals currently rate "Strong Sell" while our fundamental analysis reads "Neutral". Notable factors include a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Jul 20, 2026.

Open?$1.94
High?$1.94
Low?$1.33
Prev. Close?$1.96
Volume?1.1M
Avg. Volume?152.4K
VWAP?$1.56
Rel. Volume?7.34x
Bid / Ask
Bid?$1.36 × 10.0K
Ask?$1.40 × 3.1K
Spread?$0.04
Midpoint?$1.38
Valuation & Ratios
Market Cap?29.4M
Shares Out?15.0M
Float?13.2M
Float %?88.2%
P/E Ratio?N/A
P/B Ratio?39.98
EPS?-$0.80
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Employees
24
Market Cap
29.4M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2014-04-10
Address
3655 NOBEL DRIVE
SAN DIEGO, CA 92122
Phone: 858-926-7655
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-2/3)
Medium-Term (Wave)? Bearish(-2/3)
Short-Term (Ripple)? Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
0
Momentum?
71
Short Sent.?
49
Piotroski F-Score?4/9Mixed
Altman Z-Score?-10.35Distress
Confidence?50%Low
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?5.23%Elevated
Short Interest?691.1K
Days to Cover?4.0
Free Float13.2M
Avg Daily Volume173.0K
Settlement Date2026-06-30
Financial Health
Current Ratio?1.03Adequate
Quick Ratio?1.03Adequate
Cash Ratio?0.88Adequate
Debt/Equity?0.81Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
N/A
P/B?
Peers
100
S&P
3
39.98HIGH
P/S?
Peers
100
S&P
3
25.37HIGH
P/FCF?
N/A
EV/EBITDA?
S&P
97
-1.2CHEAP
EV/Sales?
Peers
100
S&P
11
9.88HIGH
Returns & Efficiency
ROE?
S&P
3
-1,636.7%WEAK
ROA?
S&P
3
-43.2%WEAK
Cash Flow & Enterprise
FCF?$-10163918
Enterprise Value?$11.4M
Fundamentals ratios updated end of day